Zusammenfassung
Die wichtigste Komplikation der Netzhautablösung und der vitreoretinalen Chirurgie ist die proliferative Vitreoretinopathie (PVR). Die PVR ist ein überaktivierter Prozess der Netzhautreparatur; die Proliferation von retinalen und Immunzellen führt zur Bildung von epiretinalen Membranen, deren Traktionen Netzhautablösungen verursachen. Dieser Artikel gibt einen kurzen Überblick über die Pathogenese und die chirurgische Behandlung der PVR sowie über bisherige Studien zur Testung von pharmakologischen Substanzen, die zur Inhibition der intraokulären Proliferation eingesetzt werden könnten. Zurzeit sind rein chirurgische Methoden das Mittel der Wahl zur Behandlung einer PVR. Eine PVR der Stadien B und C1 / C2 kann mit Buckelchirurgie behandelt werden. Ab dem Stadium C 3 sollte eine Vitrektomie durchgeführt werden.
Abstract
Proliferative vitreoretinopathy (PVR) is the most important complication of retinal detachment and vitreoretinal surgery. PVR is considered to represent a maladapted retinal wound repair process; proliferation of retinal and immune cells induces the formation of epiretinal membranes which cause tractional retinal detachment. This publication gives a brief overview on the pathogenesis and operative treatment of PVR as well as on adjunct pharmacological therapy which may target the components of the proliferative process. At the moment surgical approaches are the first choice for the treatment of PVR. Scleral buckling provides good anatomic results in the treatment of a PVR stage B or C1 / C2. From stage C 3 onwards vitrectomy offers advantage.
Schlüsselwörter
proliferative Vitreoretinopathie - Buckelchirurgie - Pars-plana-Vitrektomie
Key words
proliferative vitreoretinopathy - scleral buckling - pars plana vitrectomy
Literatur
-
1
Hooymans J M, De Lavalette V W, and O ey AG.
Formation of proliferative vitreoretinopathy in primary rhegmatogenous retinal detachment.
Doc Ophthalmol.
2000;
100
39-42
[PubMed]
-
2
Koerner F.
Clinical diagnosis of proliferative vitreoretinopathy.
Klin Monatsbl Augenheilkd.
1989;
194
383-388
-
3 Heimann K, Wiedemann P. ProliferativeVitreoretinopathy. Kaden Verlag; 1989
-
4
Machemer R. et al .
An updated classification of retinal detachment with proliferative vitreoretinopathy.
Am J Ophthalmol.
1991;
112
159-165
[PubMed]
-
5
Wiedemann P.
Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration.
Surv Ophthalmol.
1992;
36
373-384
[PubMed]
-
6
Charteris D G, Sethi C S, Lewis G P. et al .
Proliferative vitreoretinopathy – developments in adjunctive treatment and retinal pathology.
Eye.
2002;
16
369-374
[PubMed]
-
7
Bringmann A, Pannicke T, Grosche J. et al .
Müller cells in the healthy and diseased retina.
Prog Retin Eye Res.
2006;
25
397-424
[PubMed]
-
8
Guidry C.
The role of Müller cells in fibrocontractive retinal disorders.
Prog Retin Eye Res.
2005;
24
75-86
[PubMed]
-
9
Mitamura Y, Takeuchi S, Matsuda A. et al .
Hepatocyte growthfactor levels in the vitreous of patients with proliferative vitreoretinopathy.
Am J Ophthalmol.
2000;
129
678-680
[PubMed]
-
10
Gamulescu M A, Chen Y, He S. et al .
Transforming growth factor β2-induced myofibroblastic differentiation of human retinal pigment epithelial cells: regulation by extracellular matrix proteins and hepatocyte growth factor.
Exp Eye Res.
2006;
83
212-222
[PubMed]
-
11
Hollborn M, Francke M, Iandiev I. et al .
Early activation of inflammation- and immune response-related genes after experimental detachment of the porcine retina.
Invest Ophthalmol Vis Sci.
2008;
49
1262-1273
-
12
Tseng W, Cortez R T, Ramirez G. et al .
Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.
Am J Ophthalmol.
2004;
137
1105-1115
[PubMed]
-
13
Heimann H, Bartz-Schmidt K U, Bornfeld N. et al .
Scleral Buckling versus Primary Vitrectomy in Rhegmatogenous Retinal Detachment Study Group. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study.
Ophthalmology.
2007;
114
2142-2154
[PubMed]
-
14
Wiedemann P, Meier P.
Endoresektiondes malignen Melanoms.
Spectrum Augenheilk.
2001;
15
242-244
[PubMed]
-
15
Sobaci G. et al .
Deadly weapon-related open-globe injuries: outcome assessment by the ocular trauma classification system.
Am J Ophthalmol.
2000;
129
47-53
-
16
Dunker S. et al .
The effect of retinal cryoapplication on the vitreous.
Retina.
1997;
17
338-343
-
17
Bonnet M.
Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment.
Ophthalmologica.
1984;
188
148-152
-
18
Mietz H, Kirchhof B, Heimann K.
Anterior proliferative vitreoretinopathy in trauma and complicated retinal detachment. A histopathologic study.
Ger J Ophthalmol.
1994;
3
15-18
[PubMed]
-
19
Kreissig I, Simader E, Rose D.
Role of segmental buckling surgery in treatment of stages B and C proliferative vitreoretinopathy detachment. A long-term follow-up.
Klin Monatsbl Augenheilkd.
1994;
205
336-343
[PubMed]
-
20
Brazitikos P D, Androudi S, Christen W G. et al .
Primarypars plana vitrectomy versus scleral buckle surgery for the treatment of pseudophakic retinal detachment: a randomized clinical trial.
Retina.
2005;
25
957-964
[PubMed]
-
21
Ivanisevic M.
Conventional retinal surgery for rhegmatogenous retinal detachment with proliferative vitreoretinopathy.
Acta Med Croatica.
1995;
49
207-209
[PubMed]
-
22
Starzycka M, Bednarz A, Sobieraj A.
Probability of successful operation in very severe retinal detachment using scleral buckling procedure.
Klin Oczna.
1992;
94
194-196
[PubMed]
-
23
McDonald H R. et al .
Surgical results for proliferative vitreoretinopathy.
Eur J Ophthalmol.
1994;
4
211-217
[PubMed]
-
24
Tseng J J, Barile G R, Schiff W M. et al .
Influence of relaxing retinotomy on surgical outcomes in proliferative vitreoretinopathy.
Am J Ophthalmol.
2005;
140
628-636
-
25
Faude F, Lambert A, Wiedemann P.
360 degrees retinectomy in severe anterior PVR and PDR.
Int Ophthalmol.
1998;
22
119-123
[PubMed]
-
26
Barile G R. et al .
Neovascular complications associated with rubeosis iridis and peripheral retinal detachment after retinal detachment surgery.
Am J Ophthalmol.
1998;
126
379-389
[PubMed]
-
27
Bourke R D, Cooling R J.
Vascular consequences of retinectomy.
Arch Ophthalmol.
1996;
114
155-160
[PubMed]
-
28
Silva D J, Kwan de A, Bunce C. et al .
Predicting visual outcome following retinectomy for retinal detachment.
Br J Ophthalmol.
2008;
92
954-958
[PubMed]
-
29
Mouries O, Bonnet M.
C2F6 in the treatment of retinal detachment associated to PVR: therapeutic trial.
J Fr Ophtalmol.
1992;
15
601-604
[PubMed]
-
30
Yamamoto S, Takeuchi S.
Silicone oil and fluorosilicone.
Semin Ophthalmol.
2000;
15
15-24
[PubMed]
-
31
Quiram P A, Gonzales C R, Hu W. et al .
Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy.
Ophthalmology.
2006;
113
2041-2047
[PubMed]
-
32
Heimann H, Stappler T, Wong D.
Heavy tamponade 1: a review of indications, use, and complications.
Eye.
2008;
22
1342-1359
[PubMed]
-
33
Jonas J B. et al .
Retinal redetachment after removal of intraocular silicone oil tamponade.
Br J Ophthalmol.
2001;
85
1203-1207
[PubMed]
-
34
Halberstadt M, Domig D, Kodjikian L. et al .
PVR recurrence and the timing of silicon oil removal.
Klin Monbl Augenheilkd.
2006;
223
361-366
-
35
Jonas J B, Budde W M, Knorr H L.
Timing of retinal redetachment after removal of intraocular silicone oil tamponade.
Am J Ophthalmol.
1999;
128
628-631
[PubMed]
-
36
Coll G E. et al .
Perfluorocarbon liquid in the management of retinal detachment with proliferative vitreoretinopathy.
Ophthalmology.
1995;
102
630-638
[PubMed]
-
37
Wong D, Williams R L, German M J.
Exchange of perfluorodecalin for gas or oil: a model for avoiding slippage.
Graefes Arch Clin Exp Ophthalmol.
1998;
236
234-237
[PubMed]
-
38
Behar-Cohen F, Le Rouic J F, Chauvaud D.
Long-term comparative anatomic results of retinal detachment with vitreoretinal proliferation operated with or without using liquid perfluorocarbons.
J Fr Ophtalmol.
1999;
22
853-858
-
39
Wu W C, Kuo S L, Chen J Y.
Management of severe proliferative vitreo-retinopathy with perfluorocarbon liquids and silicone oil.
Kaohsiung J Med Sci.
1999;
15
611-6
[PubMed]
-
40
Mitamura Y, Yamamoto S, Yamazaki S.
Corneal endothelial cell loss in eyes undergoing lensectomy with and without anterior lens capsule removal combined with pars plana vitrectomy and gas tamponade.
Retina.
2000;
20
59-62
[PubMed]
-
41
Korobelnik J F. et al .
Silicone oil removal combined with macular pucker dissection: a retrospective review of 14 cases.
Retina.
1998;
18
228-232
[PubMed]
-
42
Meurs J C. et al .
Rubeosis of the iris in proliferative vitreoretinopathy.
Retina.
1996;
16
292-295
[PubMed]
(4)
-
43
Lewis van H, Verdaguer J I.
Surgical treatment for chronic hypotony and anterior proliferative vitreoretinopathy.
Am J Ophthalmol.
1996;
122
228-235
[PubMed]
-
44
Wiedemann P. et al .
Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial.
Am J Ophthalmol.
1998;
126
550-559
[PubMed]
-
45
Asaria R HY, Kon C H, Bunce C. et al .
Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial.
Ophthalmology.
2001;
108
1179-1183
[PubMed]
-
46
Charteris D G, Aylward G W, Wong D. et al .
A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy.
Ophthalmology.
2004;
111
2240-2245
-
47
Hollborn M, Tenckhoff S, Jahn K. et al .
Changes in retinal gene expression in proliferative vitreoretinopathy: glial cell expression of HB-EGF.
Mol Vis.
2005;
11
397-413
[PubMed]
-
48
Behrens-Baumann W, Vogel M.
Experimental study on drug therapy of „tractionretinal detachment” after posterior penetrating eye injury in the rabbit.
Graefes Arch Clin Exp Ophthalmol.
1986;
224
513-519
-
49
Cheema R A, Peyman G A, Fang T. et al .
Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy.
Ophthalmic Surg Lasers Imaging.
2007;
38
365-370
-
50
Lewis G, Mervin K, Valter K. et al .
Limiting the proliferation and reactivity of retinal Müller cells during experimental retinal detachment: the value of oxygen supplementation.
Am J Ophthalmol.
1999;
128
165-172
Prof. Dr. Peter Wiedemann
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Leipzig AöR
Liebigstr. 10 – 14
04103 Leipzig
Phone: ++ 49/3 41/9 72 16 50
Email: augen@medizin.uni-leipzig.de
